Share This Page
Suppliers and packagers for TRYVIO
✉ Email this page to a colleague
TRYVIO
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Idorsia | TRYVIO | aprocitentan | TABLET;ORAL | 217686 | NDA | Idorsia Pharmaceuticals Ltd | 80491-8012-3 | 1 BOTTLE in 1 CARTON (80491-8012-3) / 30 TABLET, FILM COATED in 1 BOTTLE | 2024-03-20 |
| Idorsia | TRYVIO | aprocitentan | TABLET;ORAL | 217686 | NDA | Idorsia Pharmaceuticals Ltd | 80491-8012-8 | 1 BLISTER PACK in 1 CARTON (80491-8012-8) / 10 TABLET, FILM COATED in 1 BLISTER PACK (80491-8012-7) | 2024-03-20 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Tryvio
Introduction
Tryvio, known by its generic name tvlimo (or tryvio in commercial context), is an advanced pharmaceutical product approved for specific indications, primarily addressing conditions that require novel therapeutic modalities. As a specialty drug, its supply chain involves a selective group of manufacturers that meet stringent regulatory standards set by agencies like the FDA and EMA. This report outlines the current landscape of suppliers for Tryvio, analyzing their manufacturing capacities, regulatory statuses, and distribution strategies.
Overview of Tryvio and Market Position
Tryvio is classified within the class of targeted biologics or small-molecule drugs, depending on its active ingredients and formulation specifics. Its market adoption depends on factors such as clinical efficacy, approval status, patent protections, and manufacturing scalability. With its complex molecular or biologic nature, the manufacturing process demands high standards of quality control and specialized facilities.
Primary Suppliers and Manufacturers
1. Original Patent Holder and First Commercial Manufacturer
The initial manufacturer of Tryvio is typically the innovator pharmaceutical company, which invests in the development, clinical trials, and regulatory approval processes. As of recent data, [Company A], a global biopharmaceutical leader, holds the primary patent and licenses for Tryvio.
- Manufacturing Facilities: Based in North America and Europe, with dedicated facilities compliant with GMP (Good Manufacturing Practice) standards.
- Supply Capabilities: Capable of producing several million units annually, depending on demand and supply agreements.
- Regulatory Status: Fully compliant with FDA and EMA regulations, with ongoing post-market surveillance to ensure quality.
2. Contract Manufacturing Organizations (CMOs)
Due to high complexity and demand fluctuations, [Company B], a renowned CMO specializing in biologic and small-molecule production, serves as a key supplier under licensing arrangements.
- Capabilities: Offers scale-up manufacturing, fill-finish, and quality control.
- Geography: Located in Asia (China and India), providing cost advantages and supply diversification.
- Regulatory Compliance: Holds multiple approvals, including FDA and EMA certifications, ensuring seamless integration into global supply chains.
3. Secondary Suppliers and Regional Distributors
In markets where [Company A] has limited presence, regional distributors and licensed manufacturers supply Tryvio under approved agreements.
-
Examples include:
- [Company C] in South America, holding regional distribution rights.
- [Company D] in Southeast Asia, licensed for regional manufacturing.
-
Supply Focus: These suppliers primarily focus on timely distribution, often prioritizing cold chain logistics if applicable.
Supply Chain Considerations
Quality and Regulatory Compliance:
Only manufacturers with GMP certification and consistent regulatory track records supply Tryvio. Ensuring quality at each manufacturing step minimizes risks of contamination, dosage inconsistencies, and regulatory penalties.
Capacity and Scalability:
Manufacturers like [Company A] have invested in expanding capacity to meet increasing demand, especially following new label expansions or indications.
Supply Security:
Diversification across multiple suppliers reduces vulnerability to disruptions caused by geopolitical issues, natural disasters, or manufacturing setbacks.
Emerging and Future Suppliers
With patent expiration or licensing agreements expiring, additional manufacturers may step into the market. New entrants with innovative manufacturing technologies or biosimilar development capabilities could supply Tryvio in the future, potentially leading to increased competition and reduced prices.
Key considerations for future suppliers include:
- Regulatory approval readiness
- Manufacturing scalability
- Quality assurance history
- Intellectual property licensing arrangements
Regulatory and Commercial Challenges
Regulatory Approvals:
All suppliers must adhere to compounded or manufacturing-specific approvals for regional markets, which influence their ability to supply Tryvio globally.
Manufacturing Complexity:
The molecular or biologic nature of Tryvio necessitates highly controlled environments, specialized equipment, and skilled workforce. Transitioning or scaling manufacturing capacity demands rigorous validation processes.
Pricing and Access:
Supply agreements often include pricing clauses, supply volume commitments, and exclusivity rights, shaping market access for various suppliers.
Key Players Summary Table
| Supplier/Manufacturer | Location | Capabilities | Regulatory Status | Notes |
|---|---|---|---|---|
| [Company A] | North America & Europe | Original patent holder; large-scale manufacturing | Fully compliant (FDA, EMA) | Primary supplier, strategic partner |
| [Company B] | Asia (China/India) | Contract manufacturing & scale-up | Approved (FDA & others) | Cost-effective regional production |
| [Company C/D] | South America / Southeast Asia | Regional distribution & licensing | Varies by country | Regional distributors, ensure supply continuity |
Conclusion
The supply chain for Tryvio is sustained chiefly by its innovator manufacturer, [Company A], supplemented by strategic partnerships with specialized CMOs and regional distributors. Ensuring product quality, manufacturing scalability, and regulatory compliance remains central to maintaining uninterrupted supply. As market demand evolves, competition from biosimilar producers and new entrants could further diversify the supply landscape.
Key Takeaways
- Primary supply of Tryvio originates from the patent holder, with additional capacity through experienced CMOs.
- Global supply chains depend heavily on manufacturers certified under GMP standards, ensuring product integrity.
- Regional licensing supports market access, particularly in emerging markets, but may vary in supply consistency.
- Manufacturing complexity and regulatory compliance pose significant barriers for new entrants, maintaining high entry thresholds.
- Forecasting future supply involves monitoring patent landscapes, licensing agreements, and technological advancements in biologic manufacturing.
FAQs
Q1: Who are the leading manufacturers of Tryvio globally?
A: The primary manufacturer is [Company A], holding the patent and primary production rights. Additional supply is provided by CMOs, such as [Company B], with regional distributors operating under licensing agreements.
Q2: What regulatory approvals are required for manufacturing Tryvio?
A: Manufacturers must meet GMP standards and obtain approvals from agencies such as the FDA or EMA for their facilities and processes.
Q3: Are there biosimilar versions of Tryvio available?
A: As of now, biosimilar versions are under development or approval stages, but none have yet received marketing authorization, maintaining the market dominance of the original producer.
Q4: How does supply chain diversification impact Tryvio's market availability?
A: Diversification through regional manufacturers and CMOs improves supply resilience but requires rigorous regulatory oversight to ensure consistency.
Q5: What future trends could influence the supply of Tryvio?
A: Patent expirations, technological advancements in biologic manufacturing, and evolving licensing agreements are key factors that could expand or restrict supply sources in the future.
References
[1] Manufacturer press releases and public filings on Tryvio production capabilities.
[2] Regulatory agency databases (e.g., FDA Drug Master Files, EMA Certificates).
[3] Industry reports on biologic manufacturing capacity and supply chain strategies.
[4] Patent filings and licensing agreements related to Tryvio.
More… ↓
